STOCK TITAN

Tourmaline Bio (TRML) Stock News, Oct 2023-Jan 2024

TRML

Tourmaline Bio Inc reports clinical, financial, and corporate developments for a late-stage biotechnology company focused on immune and inflammatory diseases. Its recurring updates center on pacibekitug, also referred to as TOUR006, including data from the Phase 2 TRANQUILITY trial in cardiovascular inflammation and program activity in thyroid eye disease.

Company news also covers quarterly financial results, business highlights, scientific meeting presentations, biomarker data involving high-sensitivity C-reactive protein and IL-6 pathway activity, advisory-board activity, material agreements, governance matters, shareholder voting topics, capital-structure disclosure, and risk factors tied to its clinical-development strategy.

-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-59.93%
Tags
private placement acquisition

FAQ

What is the current stock price of Tourmaline Bio (TRML)?

Tourmaline Bio (TRML) last closed at $47.98.